Please wait
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 15


  

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number:  000-50571

 

Response Biomedical Corp.

(Exact name of registrant as specified in its charter)

 

1781 - 75th Avenue W.

Vancouver, British Columbia, Canada V6P 6P2

(Address of principal executive offices, including zip code)

 

Common Stock without par value 

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

 

Rule 12g-4(a)(1)

 

 

 

 

 

Rule 12g-4(a)(2)

 

 

 

 

 

Rule 12h-3(b)(1)(i)

 

 

 

 

 

Rule 12h-3(b)(1)(ii)

 

 

 

 

 

Rule 15d-6

 

 

 

 

 

 

 

 

 

 

 

 

Approximate number of holders of record as of the certification or notice date: one (1).

 

 

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

     

RESPONSE BIOMEDICAL CORPORATION

 
           

Date:

December 2, 2016

 

By:

 /s/Barbara R. Kinnaird

 

 

 

 

Name:

Barbara R. Kinnaird

 

 

 

 

Title:

Chief Executive Officer